Dendreon Says Provenge On Track For Steady Growth, Downplays Rising Competition
This article was originally published in The Pink Sheet Daily
Executive Summary
In an earnings call Nov. 2, Dendreon reported Q3 growth in sales and uptake of its prostate cancer active immunotherapy Provenge despite near term pressures.